Official UK visa sponsor profile for Scancell Limited in Nottingham, including current register status, route details, and public company data.
Scancell Limited is a clinical-stage biotechnology company focused on developing innovative immunotherapy therapies for significant unmet medical needs. Established in 1996 and currently operating under Reg: 03234881, Scancell is headquartered at Bellhouse Building, Sanders Road, Oxford, OX4 4GD. The company’s core business centers on research and development of novel immunotherapeutic approaches targeting specific cancer pathways. Scancell specializes in utilizing a unique, proprietary technology platform that allows for targeted delivery of immune cells to enhance anti-tumor responses. Scancell’s primary focus is on oncology, with a particular emphasis on treating cancers exhibiting complex immune evasion mechanisms. The company’s international presence includes strategic partnerships and collaborations across multiple regions. Currently, Scancell is classified as a Ltd. and operates within the SIC codes of -72110 – Research and experimental development on biotechnology. The company is currently employing a skilled worker visa and holds a Worker (A) rating, indicating a high level of capability and commitment to its work. Scancell is actively seeking to expand its international reach and accelerate the development of its therapeutic candidates.
Official UK visa sponsor profile for Scancell Limited in Nottingham, including current register status, route details, and public company data.
Scancell Limited is a clinical-stage biotechnology company focused on developing innovative immunotherapy therapies for significant unmet medical needs. Established in 1996 and currently operating under Reg: 03234881, Scancell is headquartered at Bellhouse Building, Sanders Road, Oxford, OX4 4GD. The company’s core business centers on research and development of novel immunotherapeutic approaches targeting specific cancer pathways. Scancell specializes in utilizing a unique, proprietary technology platform that allows for targeted delivery of immune cells to enhance anti-tumor responses. Scancell’s primary focus is on oncology, with a particular emphasis on treating cancers exhibiting complex immune evasion mechanisms. The company’s international presence includes strategic partnerships and collaborations across multiple regions. Currently, Scancell is classified as a Ltd. and operates within the SIC codes of -72110 – Research and experimental development on biotechnology. The company is currently employing a skilled worker visa and holds a Worker (A) rating, indicating a high level of capability and commitment to its work. Scancell is actively seeking to expand its international reach and accelerate the development of its therapeutic candidates.
Yes, Scancell Limited is listed on the Home Office register of licensed sponsors. They are licensed for the Skilled Worker route.
Scancell Limited is classified under: Research and experimental development on biotechnology.
Available visa routes:
* Costs are estimates based on 2026 rates. Actual costs may vary.
Ask AI about visa requirementsSponsor licenses change frequently. Always verify on the official GOV.UK register before applying.
Yes, Scancell Limited is listed on the Home Office register of licensed sponsors. They are licensed for the Skilled Worker route.
Scancell Limited is classified under: Research and experimental development on biotechnology.
Available visa routes:
* Costs are estimates based on 2026 rates. Actual costs may vary.
Ask AI about visa requirementsSponsor licenses change frequently. Always verify on the official GOV.UK register before applying.